Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05
- Authors
- Park, Ji Hyun; You, Gun Lyung; Ahn, Myung-Ju; Kim, Sang-We; Hong, Min Hee; Han, Ji-Youn; Ock, Chan-Young; Lee, Jong-Seok; Oh, In Jae; Lee, Shin Yup; Kim, Cheol Hyeon; Min, Young Joo; Choi, Yoon Hee; Ryu, Jeong-Seon; Park, Sun Hyo; Ahn, Hee Kyung; Shim, Byoung-Yong; Lee, Ki Hyeong; Lee, Sung Yong; Kim, Jin-Soo; Yi, Jiun; Choi, Su Kyung; An, Hyonggin; Kang, Jin Hyoung
- Issue Date
- Aug-2021
- Publisher
- SPRINGER
- Keywords
- Biomarkers; Immune-checkpoint inhibitor; Non-small cell lung cancer; PD-L1; Real-world; irAE
- Citation
- JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, v.147, no.8, pp.2459 - 2469
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Volume
- 147
- Number
- 8
- Start Page
- 2459
- End Page
- 2469
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/136894
- DOI
- 10.1007/s00432-021-03527-4
- ISSN
- 0171-5216
- Abstract
- Purpose Although immune-checkpoint inhibitors have become a new therapeutic option for recurrent/metastatic non-small cell lung cancers (R/M-NSCLC), its clinical benefit in the real-world is still unclear. Methods We investigated 1181 Korean patients with programmed death-1 ligand 1 (PD-L1)-positive [tumor proportion score (TPS) >= 10% by the SP263 assay or >= 50% by the 22C3 assay] R/M-NSCLC treated with pembrolizumab or nivolumab after failure of platinum-based chemotherapy. Results The median age was 67 years, 13% of patients had ECOG-PS >= 2, and 27% were never-smokers. Adenocarcinoma was predominant (61%) and 18.1% harbored an EGFR activating mutation or ALK rearrangement. Pembrolizumab and nivolumab were administered to 51.3% and 48.7, respectively, and 42% received them beyond the third-line chemotherapy. Objective response rate (ORR) was 28.6%. Pembrolizumab group showed numerically higher ORR (30.7%) than the nivolumab group (26.4%), but it was comparable with that of the nivolumab group having PD-L1 TPS >= 50% (32.4%). Median progression-free survival (PFS) and overall survival (OS) were 2.9 (95% CI 0-27.9) and 10.7 months (95% CI 0-28.2), respectively. In multivariable analysis, concordance of TPS >= 50% in both PD-L1 assays and the development of immune-related adverse events (irAEs) were two significant predictors of better ORR, PFS, and OS. EGFR mutation could also predict significantly worse OS outcomes. Conclusion The real-world benefit of later-line anti-PD1 antibodies was comparable to clinical trials in patients with R/M-NSCLC, although patients generally were more heavily pretreated and had poorer ECOG-PS. Concordantly high PD-L1 TPS >= 50% and development of irAE could independently predict better treatment outcomes, while EGFR mutation negatively affected OS.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholar.korea.ac.kr/handle/2021.sw.korea/136894)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.